Jacobio Pharmaceuticals Group Co., Ltd.

As of December 31, 2025, Jacobio Pharmaceuticals Group Co Ltd. carries a market capitalization of 747.47M, placing it among publicly traded companies globally. Its enterprise value stands at 613.25M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Jacobio Pharmaceuticals Group Co Ltd.'s next confirmed earnings release is scheduled for March 24, 2027.

As of December 31, 2025, Jacobio Pharmaceuticals Group Co Ltd. has 787.06M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Jacobio Pharmaceuticals Group Co Ltd. maintains a current ratio of 5.10, meaning it holds 5.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on September 29, 2026, Jacobio Pharmaceuticals Group Co Ltd.'s stock has declined approximately 12.86% over the past 52 weeks.

As of December 31, 2025, Jacobio Pharmaceuticals Group Co Ltd. holds 157.83M in cash and equivalents against 23.62M in total debt, resulting in a net debt position of -121.40M. Total book value stands at 110.21M, with working capital of 132.64M providing operational flexibility.